The role of erlotinib in advanced NSCLC

Goldsack, N.
November 2005
Thorax;Nov2005, Vol. 60 Issue 11, p931
Academic Journal
The article focuses on the role of erlotinib in advanced non-small cell lung cancer (NSCLC). Relapsed advanced NSCLC carries a dismal prognosis and new treatments are particularly welcome. The article examines the use of erlotinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) in patients with NSCLC that has advanced despite prior chemotherapy. The article was double blind and 731 patients with good performance status who had had at least one prior course of chemotherapy were randomized to receive either oral erlotinib or placebo. In the treated group overall survival was improved by 2 months. Factors predicting response to treatment were being a non-smoker, adenocarcinoma on histology, and expression of EGFR in biopsy specimens. Survival was not affected by EGFR receptor expression or EGFR mutations.


Related Articles

  • Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. Tartarone, Alfredo; Lerose, Rose; Gallucci, Giuseppina; Ardito, Raffaele; Aieta, Michele // Medical Oncology;Sep2012, Vol. 29 Issue 3, p1599 

    Treatment for patients with advanced NSCLC generally consists of chemotherapy, but response rates are modest and recurrence occurs for most patients after standard first-line platinum-based doublet therapy. Tailoring therapy to individual patient according to certain prognostic and predictive...

  • Gefitinib improved survival vs. cisplatin/docetaxel in patients with NSCLC, EGFR mutations.  // Hem/Onc Today;1/25/2010, Vol. 11 Issue 2, p25 

    The article focuses on a study which found that patients with non-small cell lung cancer who have epidermal growth factor receptor mutations had superior progression free survival (PFS) when assigned gefitinib compared with standard platinum doublet chemotherapy.

  • Is EGFR expression important in non-small cell lung cancer? Lee, S. M. // Thorax;Feb2006, Vol. 61 Issue 2, p98 

    The article discusses a meta-analysis of 18 studies aimed at reviewing whether epidermal growth factor receptor (EGFR) overexpression in non-small cell lung cancer (NSCLC) has an impact on survival. Nakamura and colleagues concluded that EGFR protein overexpression using the immunohistochemistry...

  • Ask the Investigator: Integration of Molecular Targeted Therapy Into the Management of Non-Small Cell Lung Cancer. Jardine, Stephanie // ONS Connect;Aug2009 Spotlight on Symposia, Vol. 24 Issue 8, p33 

    Information about topics discussed at the moderated session held at the Marriott Rivercenter Hotel in San Antonio, Texas is presented. Topics include research supporting the approval of bevacizumab plus chemotherapy for small cell lung cancer, diverse clinical manifestations of epidermal growth...

  • Cetuximab: a new hope for advanced NSCLC. Karmali, S. // Thorax;Oct2009, Vol. 64 Issue 10, p907 

    The article focuses on a randomized study which investigates a monoclonal antibody against the epidermal growth factor receptor (EGFR), cetuximab, as a treatment option for advanced non-small cell lung cancers. The study randomly assigns patients to chemotherapy with cetuximab or chemotherapy...

  • New Directions in Oncology Nursing Care: Focus on Gefitinib in Patients With Lung Cancer. Pizzo, Barbara // Clinical Journal of Oncology Nursing;Aug2004, Vol. 8 Issue 4, p385 

    Provides information on the use of cytotoxic chemotherapy in the treatment of solid tumors. Description of the molecular-targeted therapy Gefitinib; Treatment of non-small cell lung cancer; Roles of epidermal growth factor receptor-tyrosine kinase in solid tumors.

  • T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. Chunyan Ma; Shuzhen Wei; Yong Song // Journal of Thoracic Disease;Mar2011, Vol. 3 Issue 1, p10 

    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as geitinib and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer (NSCLC). Patients with somatic activating mutations in the EGFR gene have dramatic response initially, but would...

  • Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. R Dziadziuszko; B Holm; BG Skov; K Osterlind; MV Sellers; WA Franklin; PA Bunn; M Varella-Garcia; FR Hirsch // Annals of Oncology;Mar2007, Vol. 18 Issue 3, p447 

    Background: Survival benefit of non-small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is predicted by high EGFR gene copy number and by strong EGFR protein expression. Clinical relevance of these features in patients treated...

  • Erlotinib seals the deal in NSCLC treatment. Salmon, Kimberley // PharmacoEconomics & Outcomes News;10/20/2007, Issue 539, p3 

    Lung cancer is the leading cause of cancer-related death in many countries, and non-small cell lung cancer (NSCLC) is the predominant diagnosis. However, this disease can be difficult to treat, with many patients not presenting until the advanced stage, and therefore facing a poor prognosis....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics